Advertisement

New and Integrated Approaches to Successful Accelerated Drug Development

  • Anthony ClementoEmail author
Article

Abstract

Traditionally, the development of a new drug from discovery to market takes 10 to 15 years and costs hundreds of millions of dollars. Accelerated drug development, therefore, is of critical importance to both maximizing return on this investment and bringing drugs for unmet medical needs to patients as rapidly as possible. New structure-based development strategies are being combined with integrated, multidisciplinary approaches to speed the processes of physicochemical and pharmacological characterization, toxico-logical investigation, and clinical testing. The process of accelerated drug development, however, presents unique challenges as well as opportunities.

Key Words

Clinical testing Accelerated drug development Drug discovery Preclinical testing Product development Research 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    DeMasi JA. Trends in drug development: costs, times, and risks. Drug Inf J. 1995;29:375–384.CrossRefGoogle Scholar
  2. 2.
    Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 1997;49:403–449.PubMedGoogle Scholar
  3. 3.
    DeMasi JA, Hansen RW, Grabowski HG, Lasagna L. Research and development costs for new drugs by therapeutic category. Pharma Econ. 1995;7:152–169.CrossRefGoogle Scholar
  4. 4.
    Kleinberg ML, Wanke LA. New approaches and technologies in drug design and discovery. Am J Health SystPharm. 1995;52:1323–1336;1341–1343.CrossRefGoogle Scholar
  5. 5.
    Andersen Consulting. Pharmaceutical & Medical Products Executive Briefing. Drug Discovery: Innovation and Productivity. 1998:1–26.Google Scholar
  6. 6.
    Bugg CE, Carson WM, Montgomery JA. Drugs by design. Sci Am. 1993;269:92–98.CrossRefGoogle Scholar
  7. 7.
    Ziai MR, Beer B. Making business sense of science with rational drug design. Pharm Exec. 1990;10:40, 42, 44, 46.Google Scholar
  8. 8.
    Hayes AH, Jr. Safety considerations in product development. Drug Saf. 1990;5(suppl):24–26.CrossRefGoogle Scholar
  9. 9.
    Establishment of Prescription Drug User Fee Rates for Fiscal Year 1998. Federal Register. 1997;62(236):64849–64851.Google Scholar

Copyright information

© Drug Information Association, Inc 1999

Authors and Affiliations

  1. 1.Regulatory AffairsCovance Laboratories, Inc.MadisonUSA

Personalised recommendations